ZA200601040B - Preparation of 1,3-diphenylprop-2-en-1-one derivatives - Google Patents
Preparation of 1,3-diphenylprop-2-en-1-one derivatives Download PDFInfo
- Publication number
- ZA200601040B ZA200601040B ZA200601040A ZA200601040A ZA200601040B ZA 200601040 B ZA200601040 B ZA 200601040B ZA 200601040 A ZA200601040 A ZA 200601040A ZA 200601040 A ZA200601040 A ZA 200601040A ZA 200601040 B ZA200601040 B ZA 200601040B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- previous
- acid
- diphenylprop
- substituted
- Prior art date
Links
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical class C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 12
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 11
- -1 thionitroso group Chemical group 0.000 claims description 10
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 5
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 238000007792 addition Methods 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims description 2
- QFMNMSJTKVHTSY-UHFFFAOYSA-N 1-phenylethanethione Chemical compound CC(=S)C1=CC=CC=C1 QFMNMSJTKVHTSY-UHFFFAOYSA-N 0.000 claims description 2
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical class OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- MWAFWBDWAWZJGK-UHFFFAOYSA-N 3,3-diphenylprop-2-enal Chemical group C=1C=CC=CC=1C(=CC=O)C1=CC=CC=C1 MWAFWBDWAWZJGK-UHFFFAOYSA-N 0.000 claims 1
- 238000006085 Schmidt reaction Methods 0.000 claims 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- BZLYUDJOVAMKIB-UHFFFAOYSA-N 2-hydroxy-1,3-diphenylprop-2-en-1-one Chemical compound C=1C=CC=CC=1C(=O)C(O)=CC1=CC=CC=C1 BZLYUDJOVAMKIB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000005882 aldol condensation reaction Methods 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N chalcone Chemical group C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 3
- 239000012707 chemical precursor Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940093956 potassium carbonate Drugs 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical class OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ACOOSTZBTYEGER-UHFFFAOYSA-N thiobenzaldehyde Chemical compound S=CC1=CC=CC=C1 ACOOSTZBTYEGER-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/31—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/65—Halogen-containing esters of unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
- C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0308354A FR2857361B1 (fr) | 2003-07-08 | 2003-07-08 | PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200601040B true ZA200601040B (en) | 2007-05-30 |
Family
ID=33522868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200601040A ZA200601040B (en) | 2003-07-08 | 2006-02-06 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7385082B2 (enExample) |
| EP (1) | EP1644312B1 (enExample) |
| JP (1) | JP2007516189A (enExample) |
| KR (1) | KR20060030110A (enExample) |
| CN (1) | CN1819986B (enExample) |
| AT (1) | ATE468317T1 (enExample) |
| AU (1) | AU2004255905B2 (enExample) |
| BR (1) | BRPI0412370A (enExample) |
| CA (1) | CA2531443C (enExample) |
| DE (1) | DE602004027251D1 (enExample) |
| DK (1) | DK1644312T3 (enExample) |
| EA (1) | EA010410B1 (enExample) |
| ES (1) | ES2343803T3 (enExample) |
| FR (1) | FR2857361B1 (enExample) |
| IL (1) | IL172825A (enExample) |
| MX (1) | MXPA06000159A (enExample) |
| NO (1) | NO332411B1 (enExample) |
| NZ (1) | NZ544792A (enExample) |
| PL (1) | PL213226B1 (enExample) |
| SG (1) | SG129448A1 (enExample) |
| WO (1) | WO2005005369A1 (enExample) |
| ZA (1) | ZA200601040B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2841784B1 (fr) * | 2002-07-08 | 2007-03-02 | Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations | |
| FR2841900B1 (fr) * | 2002-07-08 | 2007-03-02 | Genfit S A | Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations |
| ES2441665T3 (es) | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| PH12012502213A1 (en) | 2010-05-17 | 2015-10-09 | Genfit | Improved preparation of chalcone derivatives |
| SI2948137T1 (sl) * | 2013-01-18 | 2019-01-31 | Genfit | Metode zdravljenja fibroz in rakov |
| EP3416629A4 (en) | 2016-02-16 | 2019-08-07 | CoNCERT Pharmaceuticals, Inc. | DEUTERATED GFT-505 |
| CN106674069B (zh) * | 2016-12-06 | 2018-05-11 | 上海博志研新药物技术有限公司 | Gft505及其中间体的制备方法 |
| WO2018133705A1 (zh) * | 2017-01-22 | 2018-07-26 | 苏州科睿思制药有限公司 | Gft-505的晶型及其制备方法和用途 |
| SG11201906987RA (en) | 2017-02-21 | 2019-09-27 | Genfit | Combination of a ppar agonist with a fxr agonist |
| WO2019025017A1 (en) | 2017-08-04 | 2019-02-07 | Advitech Advisory And Technologies Sa | PROCESS FOR THE PREPARATION OF ELAFIBRANOR AND NEW SYNTHETIC INTERMEDIATES |
| EP3710425A1 (en) | 2017-11-16 | 2020-09-23 | Teva Pharmaceuticals International GmbH | Solid state forms of elafibranor |
| CN109608318A (zh) * | 2019-01-31 | 2019-04-12 | 上海生农生化制品股份有限公司 | 一种戊唑醇中间体α的工业合成方法 |
| CN110156648A (zh) * | 2019-05-30 | 2019-08-23 | 河北科技大学 | 一种Elafibranor中间体的制备方法 |
| CN110143890B (zh) * | 2019-06-12 | 2020-12-22 | 天津科技大学 | 一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用 |
| CN110143902B (zh) * | 2019-06-12 | 2021-06-04 | 天津科技大学 | 含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用 |
| US20230008367A1 (en) | 2019-09-26 | 2023-01-12 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN113121394B (zh) * | 2019-12-30 | 2022-11-08 | 中国药科大学 | 一种苯氧乙酸类衍生物的制备方法 |
| KR20230011958A (ko) | 2020-05-18 | 2023-01-25 | 장피트 | 원발성 경화성 담관염의 치료를 위한 엘라피브라노 |
| WO2022043367A1 (en) | 2020-08-26 | 2022-03-03 | Genfit | Compositions and methods for the treatment of primary biliary cholangitis |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| CN113230240B (zh) * | 2021-03-22 | 2022-12-27 | 广州医科大学 | 1,3-二苯基丙-2-烯-1-酮衍生物及其应用 |
| WO2022238448A1 (en) | 2021-05-11 | 2022-11-17 | Genfit | Elafibranor derivatives agonists of ppar for use in the treatment of sepsis |
| WO2022238445A1 (en) | 2021-05-11 | 2022-11-17 | Genfit | Ppar-agonists for use in the treatment of liver failure |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2359621C2 (de) * | 1973-11-30 | 1982-11-18 | Hoechst Ag, 6000 Frankfurt | Antiviral wirksame Alkalimetall- oder Ammoniumsalze der Polyacrylsäure |
| GB8426424D0 (en) * | 1984-10-19 | 1984-11-28 | Biorex Laboratories Ltd | Chalcone derivatives |
| JPH023670A (ja) * | 1988-06-22 | 1990-01-09 | Nippon Oil & Fats Co Ltd | アルキルチオカルコン誘導体 |
| JPH05255655A (ja) * | 1992-03-12 | 1993-10-05 | Kanebo Ltd | 紫外線吸収剤 |
| US5523302A (en) * | 1993-11-24 | 1996-06-04 | The Du Pont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| EP0947511A1 (en) * | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| JPH11302243A (ja) * | 1998-04-24 | 1999-11-02 | Mitsubishi Chemical Corp | ジエチレントリアミン５酢酸誘導体 |
-
2003
- 2003-07-08 FR FR0308354A patent/FR2857361B1/fr not_active Expired - Fee Related
-
2004
- 2004-07-08 PL PL379543A patent/PL213226B1/pl unknown
- 2004-07-08 EP EP04767629A patent/EP1644312B1/fr not_active Expired - Lifetime
- 2004-07-08 CA CA2531443A patent/CA2531443C/fr not_active Expired - Fee Related
- 2004-07-08 NZ NZ544792A patent/NZ544792A/en not_active IP Right Cessation
- 2004-07-08 CN CN2004800195644A patent/CN1819986B/zh not_active Expired - Lifetime
- 2004-07-08 SG SG200700644A patent/SG129448A1/en unknown
- 2004-07-08 EA EA200600197A patent/EA010410B1/ru not_active IP Right Cessation
- 2004-07-08 US US10/563,057 patent/US7385082B2/en not_active Expired - Lifetime
- 2004-07-08 AT AT04767629T patent/ATE468317T1/de active
- 2004-07-08 JP JP2006518300A patent/JP2007516189A/ja active Pending
- 2004-07-08 MX MXPA06000159A patent/MXPA06000159A/es active IP Right Grant
- 2004-07-08 KR KR1020067000562A patent/KR20060030110A/ko not_active Ceased
- 2004-07-08 WO PCT/FR2004/001797 patent/WO2005005369A1/fr not_active Ceased
- 2004-07-08 DE DE602004027251T patent/DE602004027251D1/de not_active Expired - Lifetime
- 2004-07-08 ES ES04767629T patent/ES2343803T3/es not_active Expired - Lifetime
- 2004-07-08 AU AU2004255905A patent/AU2004255905B2/en not_active Ceased
- 2004-07-08 BR BRPI0412370-0A patent/BRPI0412370A/pt not_active Application Discontinuation
- 2004-07-08 DK DK04767629.1T patent/DK1644312T3/da active
-
2005
- 2005-12-26 IL IL172825A patent/IL172825A/en unknown
-
2006
- 2006-01-06 NO NO20060087A patent/NO332411B1/no not_active IP Right Cessation
- 2006-02-06 ZA ZA200601040A patent/ZA200601040B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2531443A1 (fr) | 2005-01-20 |
| DE602004027251D1 (de) | 2010-07-01 |
| IL172825A0 (en) | 2006-06-11 |
| CA2531443C (fr) | 2012-05-01 |
| JP2007516189A (ja) | 2007-06-21 |
| IL172825A (en) | 2010-11-30 |
| ATE468317T1 (de) | 2010-06-15 |
| FR2857361B1 (fr) | 2005-09-09 |
| FR2857361A1 (fr) | 2005-01-14 |
| NZ544792A (en) | 2009-02-28 |
| NO20060087L (no) | 2006-02-07 |
| PL213226B1 (pl) | 2013-01-31 |
| EP1644312B1 (fr) | 2010-05-19 |
| EP1644312A1 (fr) | 2006-04-12 |
| US20060142611A1 (en) | 2006-06-29 |
| EA010410B1 (ru) | 2008-08-29 |
| BRPI0412370A (pt) | 2006-09-05 |
| WO2005005369A1 (fr) | 2005-01-20 |
| NO332411B1 (no) | 2012-09-17 |
| AU2004255905B2 (en) | 2010-11-18 |
| US7385082B2 (en) | 2008-06-10 |
| CN1819986A (zh) | 2006-08-16 |
| MXPA06000159A (es) | 2006-03-21 |
| EA200600197A1 (ru) | 2006-06-30 |
| ES2343803T3 (es) | 2010-08-10 |
| SG129448A1 (en) | 2007-02-26 |
| DK1644312T3 (da) | 2010-08-23 |
| CN1819986B (zh) | 2011-02-02 |
| AU2004255905A1 (en) | 2005-01-20 |
| PL379543A1 (pl) | 2006-10-02 |
| KR20060030110A (ko) | 2006-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200601040B (en) | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | |
| Yadav et al. | Organic synthesis in water: Green protocol for the conjugate addition of thiols to p-quinones | |
| KR20060129186A (ko) | 스타틴의 제조방법 | |
| CN102643237B (zh) | 1h-咪唑-4-甲酸的制备方法 | |
| AU2009263303B2 (en) | Method for producing 3-methyl-2-thiophenecarboxylic acid | |
| JP2004514716A (ja) | リポ酸およびジヒドロリポ酸の調製方法 | |
| US20190194230A1 (en) | Process for the preparation of crisaborole | |
| FR3021655A1 (fr) | Nouveaux composes de type 5-acylsulfanyl-histidine en tant que precurseurs des 5-sulfanylhistidines correspondantes et de leurs disulfures | |
| EP2239252B1 (en) | Process for producing 3-methylthiopropanal | |
| WO2004092104A1 (ja) | ２－（ｌ－メントキシ）エタノール類の製造方法 | |
| JP2000103779A (ja) | アルキルスルホニルベンズアルデヒド類の製造方法 | |
| CN102766077B (zh) | 一种制备1-苯基-2-苯磺酰基乙酮的新方法 | |
| JP3159767B2 (ja) | 新規な含硫黄化合物及びその製造方法 | |
| Dai et al. | Structural Effect on Eu (fod) 3‐Catalyzed Rearrangement of Allylic Esters | |
| JP2020125248A (ja) | タゾバクタム鍵中間体の製造方法 | |
| JP3118596B2 (ja) | アリールジアルキルチオカルバマート、２−メルカプトベンズアルデヒドおよび２−置換ベンゾ［ｂ］チオフェンの製造方法 | |
| JP3840810B2 (ja) | β−ケトアルデヒアルカリ塩の製造方法 | |
| JP2004262871A (ja) | ７−オクテン−１−オールならびに７−オクテン酸またはその誘導体の共製造方法 | |
| JPS60209548A (ja) | ２−（４−ヒドロキシフエノキシ）プロピオン酸エステルの製造方法 | |
| US7323603B2 (en) | Method for aldol reaction in water | |
| JP5573079B2 (ja) | ３−メルカプト−１−プロパノールの製造方法 | |
| WO2009082362A1 (en) | A method for producing statins in pure form | |
| JP2000239202A (ja) | ヒドロキシフェニルプロパノール類の製造方法 | |
| JP2004067560A (ja) | ヒドロキシアルキルアミン類の製造方法 | |
| JP2009292726A (ja) | ヒドラゾン類の製造法 |